ArticleOncology research2017
Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.
Article in Oncology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 41 citations in OpenAlex.
- Identification of novel genes with enriched expression in human intermediate progenitors reveals a key role for CDKN3 in cortical development.Stem cell reports · 2026Article
- [High expression of CDKN3 promotes migration and invasion of gastric cancer cells by regulating the p53/NF-κB signaling pathway and inhibiting cell apoptosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Proteogenomic characterization of difficult-to-treat breast cancer with tumor cells enriched through laser microdissection.Breast cancer research : BCR · 2024Article
- The role of Cyclin Dependent Kinase Inhibitor 3 (Heliyon · 2024Review
- Identification of CDKN3 as a Key Gene that Regulates Neuroblastoma Cell Differentiation.Journal of Cancer · 2024Article
- PSMD12 interacts with CDKN3 and facilitates pancreatic cancer progression.Cancer gene therapy · 2023Article
- CCNB1 is involved in bladder cancer pathogenesis and silencing CCNB1 decelerates tumor growth and improves prognosis of bladder cancer.Experimental and therapeutic medicine · 2023Article
- Multi-Omics Data Analysis Identifies Prognostic Biomarkers across Cancers.Medical sciences (Basel, Switzerland) · 2023Article
- Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer.International journal of general medicine · 2023Article
- Evaluation of gene expression of PLEKHS1, AADAC, and CDKN3 as novel genomic markers in gastric carcinoma.PloS one · 2022Article
- Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis.Molecular cancer · 2021Article
- A Novel DNA Damage Repair-Related Gene Signature for Predicting Glioma Prognosis.International journal of general medicine · 2021Article
- Downregulated genes by silencingAging · 2020Article
- [Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma.Journal of translational medicine · 2020Article
- CDKN3 promotes cell proliferation, invasion and migration by activating the AKT signaling pathway in esophageal squamous cell carcinoma.Oncology letters · 2020Article
- Screening of potential biomarkers and their predictive value in early stage non-small cell lung cancer: a bioinformatics analysis.Translational lung cancer research · 2019Article
- Bioinformatics analysis of key biomarkers and pathways in KSHV infected endothelial cells.Medicine · 2019Article
- Identification of putative drugs for gastric adenocarcinoma utilizing differentially expressed genes and connectivity map.Molecular medicine reports · 2019Article
- Cyclin-Dependent Kinase Inhibitor 3 Promoted Cell Proliferation by Driving Cell Cycle from G1 to S Phase in Esophageal Squamous Cell Carcinoma.Journal of Cancer · 2019Article
Corrections and comments
- Retracted
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclin-dependent kinase inhibitor 3 (CDKN3) has been reported to promote tumorigenesis. Since it is unclear whether CDKN3 participates in the development of human gastric cancer, this study assessed the association between CDKN3 expression and cell biological function and demonstrated the clinical significance and prognosis of CDKN3 in human gastric cancer. In this study, we found that CDKN3 showed a high expression in 35 paired human gastric cancer tissues and was correlated with poor patient survival, AJCC clinical staging, and recurrence. Silencing of CDKN3 in human gastric cancer cells can significantly reduce proliferation, migration, invasion, and adhesion abilities. Also, silencing of CDKN3 in human gastric cancer cells can induce G0-G1 cell cycle arrest and apoptosis. Detection of cell cycle marker expression showed that CDKN3 knockdown promotes cell cycle arrest by decreasing the expression of CDK2, CDC25A, CCNB1, and CCNB2 in human gastric cancer cells. The results of this study will help elucidate the oncogene function of CDKN3 in human gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.